Table 5.
Pharmacological treatments at baseline and after 24 weeks of therapy with sac/val.
| Baseline | Follow-up | P Value | |
|---|---|---|---|
| Variables | (n = 59) | (n = 59) | |
| ACE inhibitors, n (%) | 43 (73) | 0 (0)0 | <0.0001 |
| ARB, n (%) | 16 (27) | 0 (0) | <0.0001 |
| MRA, n (%) | 27 (46) | 25 (42) | 0.7 |
| Loop diuretics, n (%) | 58 (98) | 48 (81) | 0.002 |
| Beta-blockers, n (%) | 57 (97) | 57 (97) | 0.99 |
| Antiplatelet agents, n (%) | 30 (51) | 30 (51) | 0.99 |
| Oral anticoagulants, n (%) | 19 (32) | 19 (352) | 0.99 |
| Statins, n (%) | 49 (83) | 53 (90) | 0.2 |
| Ezetimibe, n (%) | 0 (0) | 9 (15) | <0.0001 |
ACE inhibitors, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; MRA, mineralocorticoid receptor antagonist; sac/val, sacubitril/valsartan.